Ignite Creation Date:
2024-05-05 @ 11:04 PM
Last Modification Date:
2024-10-26 @ 10:28 AM
Study NCT ID:
NCT01247194
Status:
COMPLETED
Last Update Posted:
2012-02-03
First Post:
2010-11-22
Brief Title:
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
Sponsor:
Presidio Pharmaceuticals Inc
Organization:
Presidio Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 1b Study to Assess the Safety Antiviral Efficacy and Pharmacokinetics of PPI-461 in Patients With HCV Genotype-1 Infection
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the safety tolerability antiviral effects and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010-021510-36 | EUDRACT_NUMBER | None | None |